Post-Vacc. HPV Genotype Distr. Among HIV+ and HIV- Young Women in S. Africa

疫苗接种后。

• 批准号: 7786136
• 负责人: DAVID H ADLER
• 金额: $ 12.58万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7786136
• 关键词: Accounting; Address; Adolescent; Affect; Africa; Automobile Driving; Cancer Etiology; Cervical; Cervical dysplasia; Clinical Trials; Cohort Studies; Communicable Diseases; Comorbidity; Controlled Study; DNA; DNA analysis; Developing Countries; Development; Disease; Drug Formulations; Enrollment; Epidemiologic Studies; European; Funding; Future; Genotype; Goals; Grant; HIV; HIV Seropositivity; HIV prevention trial; HIV vaccine; HPV-High Risk; Human Papilloma Virus Vaccine; Human Papillomavirus; Human papilloma virus infection; Human papillomavirus 16; Incidence; Knowledge; Life; Malignant neoplasm of cervix uteri; Mentors; Oncogenic; Pap smear; Participant; Population; Population Study; Prevalence; Preventive Intervention; Proxy; Public Health; Relative (related person); Research; Research Personnel; Research Project Grants; Site; South Africa; Specimen; Subgroup; Testing; Training; Vaccinated; Vaccination; Vaccines; Western World; Woman; base; career; control trial; design; disorder prevention; experience; men; next generation; novel vaccines; patient oriented research; public health relevance; response; sexually active; vaccination strategy

DESCRIPTION (provided by applicant): A mentored, patient-oriented, research project is proposed to provide the candidate with rigorous training and experience in studying the virologic effects of human papillomavirus (HPV) vaccine introduction. The impact of the new vaccines against HPV types 16 and 18 is uncertain. Although all cervical cancer is caused by HPVs, types 16 and 18 (i.e. the vaccine types) account for only 65-70% of cases. An additional 13-16 HPV types cause the remaining 30-35% of cases. The proposed study will assess the impact of the HPV 16/18 vaccine on the other oncogenic HPV types. The primary hypothesis of the study is that the prevalence of vaccine and non-vaccine HPV types will change as a result of vaccination against types 16 and 18. If confirmed, this would indicate that the incidence of cervical cancer from non-vaccine HPV types will change in the wake of vaccination. Considering the staggering global burden of cervical cancer, understanding how this new preventive intervention impacts the disease is a critical public health concern. The proposed study will be carried out as a sub-study within a larger European-funded project in South Africa. The three specific aims of the proposed project are: 1) To assess the impact of the quadrivalent HPV vaccine on the distribution of non-vaccine HR-HPV in the study population, 2) To determine and compare the pre- and post-vaccination distribution of HR-HPV among HIV-infected and HIV-uninfected sexually active young women in South Africa, and 3) To analyze the association of cervical dysplasia with the results of HPV DNA analysis in the study population. The fundamental design of the proposed project is a longitudinal cohort study in which sexually active young women will be tested for HPV DNA, vaccinated, and then re-tested for HPV at six month intervals. The HIV positive subgroup within our study population will receive special focus as this widely prevalent co-morbidity may effect HPV distribution and vaccine response. Pap smears of all study participants will be performed upon study enrolment and exit to enable correlation of HPV infection with cervical disease. The candidate's career goals include becoming an established, independent investigator of infectious disease prevention in the developing world. Executing the proposed project will prepare the candidate to accomplish this goal. PUBLIC HEALTH RELEVANCE: Project Narrative/Relevance Understanding how vaccination against some types of cancer-causing HPVs affects the distribution of the many other types of cancer-causing HPVs is essential to anticipating the impact of vaccination on reducing cervical cancer. During the development of the next generation of HPV vaccines, knowledge gained from the proposed project will directly address the question, "Vaccination against which HPV types will save the most women's lives?".

描述（由申请人提供）：提出一项有指导的、以患者为导向的研究项目，为候选人提供研究人乳头瘤病毒（HPV）疫苗引入的病毒学效应的严格培训和经验。针对16型和18型HPV的新疫苗的影响尚不确定。虽然所有子宫颈癌都是由人乳头瘤病毒引起的，但16型和18型（即疫苗型）只占病例的65-70%。另外13-16种HPV类型导致其余30-35%的病例。拟议的研究将评估HPV 16/18疫苗对其他致癌型HPV的影响。